Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers

Journal of Digestive Diseases

Volumn 14, Issue 6, 2013, Pages 288-298

  Xu, Xi Tao ^a,b   Dai, Zhang Han ^a,b   Xu, Qi ^a,b   Qiao, Yu Qi ^a,b   Gu, Yan ^a,b   Nie, Fang ^a,b   Zhu, Ming Ming ^a,b   Tong, Jin Lu ^a,b   Ran, Zhi Hua ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Calcium gluconate; Digestive system neoplasms; Magnesium sulfate; Neurotoxicity syndrome; Oxaliplatin

Indexed keywords

GLUCONATE CALCIUM; MAGNESIUM SULFATE; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; INCIDENCE; META ANALYSIS; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSORY NEUROPATHY;

ANTINEOPLASTIC AGENTS; CALCIUM; CHEMOPREVENTION; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84876998359     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12050     Document Type: Article

References (37)

1. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011; 14: 22-34.
2. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4: 889-901.
3. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000; 59 Suppl 4: 9-17; discussion 37-8.
4. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31: 90-105.
5. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004; 5: 2159-2170.
6. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000; 60: 895-924.
7. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007; 3: 281-294.
8. Capdevila J, Elez E, Peralta S, Macarulla T, Ramos FJ, Tabernero J. Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 2008; 8: 1223-1236.
9. Goldberg RM. Introduction: Perspectives on oxaliplatin in the treatment of gastrointestinal cancers. Semin Oncol 2003; 30: 1-4.
10. Wahba HA, El-Hadaad HA, Abd-Ellatif EA. Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer. Med Oncol 2012; 29: 1693-1698.
11. Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011; 14: 50-55.
12. Heinrich S, Pestalozzi B, Lesurtel M etal. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011; 11: 346.
13. Sun W, Sohal D, Haller DG etal. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 2011; 117: 3187-3192.
14. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005; 5 Suppl 1: S38-46.
15. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006; 59: 159-168.
16. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33.
17. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44: 1507-1515.
18. Hoff PM. Oxaliplatin-related neurotoxicity: is chelation the solution? Nat Clin Pract Oncol 2004; 1: 78-79.
19. Pederiva S, Caspar CB. Management of acute oxaliplatin-related peripheral sensory neuropathy with magnesium and calcium. 2004 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, USA (Abstract No. 282).
20. Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. J Appl Res 2004; 4: 576-582.
21. Gamelin L, Boisdron-Celle M, Delva R etal. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-4061.
22. Yang HL, Zhang LL. Clinical observation of magnesium sulfate and calcium gluconate in the prevention of oxaliplatin-induced neurotoxicity. Chin Clin Oncol 2006; 11: 66-67 (in Chinese).
23. Yu JH, Wan HP, Yu JY. Clinical study of prevention of oxaliplatin-induced acute neurotoxicity by calcium and magnesium infusions. Cancer Res Clin 2007; 19: 388-390 (in Chinese).
24. Li J, Huang LM, Ma HM. Clinical observation on preventive effect of different doses of Ca/Mg infusion on oxaliplatin-induced neurotoxicity. Inner Mongol J Tradit Chin Med 2008; 27: 15-16 (in Chinese).
25. Yan Y, Zhou K, Fan QX. Clinical observation of prevention of oxaliplatin-induced neurotoxicity with magnesium sulfate and calcium gluconate. Shandong Med J 2008; 48: 80-81 (in Chinese).
26. Ke YF, Peng ZQ. Clinical observation of calcium and magnesium infusions in the prevention of oxaliplatin-induced neurotoxicity. Jiangxi Med J 2009; 44: 604-605 (in Chinese).
27. Li MY, Xu JM, Song ST, Chen JP. A clinical trial of Ca and Mg mixture for preventing oxaliplatin-induced neurotoxicity. J Oncol 2009; 15: 450-452 (in Chinese).
28. Li Y, Li YH, Fan QX, Wang LX. The effect of magnesium sulfate and calcium gluconate in prevention of oxaliplatin-induced neurotoxicity in 25 cases with gastrointestinal tumors. J Zhengzhou Univ (Med Sci) 2009; 44: 897-898 (in Chinese).
29. Xing SC, Shen LQ, Zhuang ZX. Clinical observation of magnesium sulfate and calcium gluconate in prevention and treatment of oxaliplatin-induced neurotoxicity. Chin J Misdiagn 2009; 9: 778-779 (in Chinese).
30. Mahfoud T, Khmamouche MR, Ismaili N etal. Use of calcium and magnesium with oxaliplatin in metastatic colorectal cancer is beneficial. Ann Oncol 2010; 21 Suppl 6: vi71.
31. Grothey A, Nikcevich DA, Sloan JA etal. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-427.
32. Knijn N, Tol J, Koopman M etal. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47: 369-374.
33. Kono T, Mamiya N, Chisato N etal. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med 2011; 2011: 418481.
34. Chay WY, Tan SH, Lo YL etal. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 2010; 6: 270-277.
35. Dong M, Xing PY, Liu P, Feng FY, Shi YK. Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity. Chin J Oncol 2010; 32: 208-211 (in Chinese).
36. Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010; 15: 82-87.
37. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007; 25: 4028-4029.